MYT1 and neoplasm: Meanwhile, ZNF300 might activate CDK1 through inhibition of WEE1 and MYT1 and modulation of the MYC/AURKA/BORA/PLK1 axis to promote the tumour cells to overcome G2 arrest and enter the M phase to avoid the apoptosis induced by chemotherapeutic drugs.